Waldenström's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in 2 7
we wanted to determine whether it plays a role in WM cell biology. We compared the IgM associated pathology of WM are likely dependent on BLIMP1 for secretion.
4 6
We subsequently chose to focus mainly on the RP cell line as it had the most uniform 1 4 7 BLIMP1 expression. In this study we show for the first time that the plasma cell master regulator
BLIMP1 has a crucial role in WM cell survival and maintains the protein levels of the 3 9 9
histone methyltransferase EZH2, demonstrating a more complex functional 4 0 0 interaction between BLIMP1 and EZH2 than previously thought [17, [32] [33] [34] .
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Furthermore, we show that the factors mediate the evasion of immune surveillance, as MYD88 signalling in B cells [29] , and BLIMP1 expression is increased in tumours 4 0 9
harbouring the MYD88 L265P activating mutation in WM [30] . However, heterozygous specific surface molecule CD20 at least in part through NK-cell engagement [68] .
2 4
However, the plasma cells remaining after this treatment present one of the biggest 4 2 5 challenges in WM therapy [69] . Futhermore, rituximab is not recommended for 4 2 6
patients exhibiting high serum IgM levels [70] , due to the risks of an IgM 'flare' 4 2 7
following treatment [71] . This highlights the importance of the antibody-secreting 4 2 8 CD20 low or negative plasma cell compartment in WM [69, 72] , which is likely maintained by BLIMP1. plasma cell leukemia phenotype [40, 75] . Our results indicate that the effects of 4 3 7
BLIMP1 on EZH2 levels might extend to myeloma, and perhaps other tumours where
the two factors are co-expressed, and warrants further study. producing cytotoxic T cells [78] . This finding together with our current study make immune-cell mediated killing. In conclusion, we provide evidence for a crucial role of BLIMP1 in promoting 4 5 9
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